Search
Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
smpdb.ca/view/SMP0250046MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
smpdb.ca/view/SMP0251290MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
smpdb.ca/view/SMP0251328MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z))
smpdb.ca/view/SMP0255947MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(18:4(6Z,9Z,12Z,15Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
smpdb.ca/view/SMP0255986MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/18:4(6Z,9Z,12Z,15Z))
smpdb.ca/view/SMP0287283MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Cardiolipin Biosynthesis CL(20:4(5Z,8Z,11Z,14Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)/20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))
smpdb.ca/view/SMP0287286MetabolicLast, cardiolipin synthase catalyzes the synthesis of cardiolipin by transferring a phosphatidyl group from a second CDP-diacylglycerol to PG. It requires a divalent metal cation cofactor.
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. … Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: JANTY 5 MG FİLM KAPLI TABLET, 56 ADET, TOFİK 5 MG FİLM KAPLI TABLET, 56 ADETTyphoid Vi polysaccharide vaccine
go.drugbank.com/drugs/DB10803ApprovedInvestigationalTyphoid Vi polysaccharide vaccine is a vaccine that is administered intramuscularly. … It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older.
Synonyms: Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strainProducts: TYPHIM VI 0,5 ML IM/SC ENJEKSİYON İÇİN ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TYPHIM VI INJECTION 0.025 mg/0.5 mlMoexipril
go.drugbank.com/drugs/DB00691ApprovedInvestigationalMoexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension).
Mixtures: UNIRETIC 15 MG/ 25 MG FILM KAPLI TABLET, 30 ADET, UNIRETIC 7,5 MG/ 12.5 MG FILM KAPLI TABLET, 30 ADETCategories: Heterocyclic Compounds, 2-Ring, Agents Acting on the Renin-Angiotensin System